 |
5 Diseases |  |
0 Trials |
|
0 Trials |  |
19 News |  |
- betamethasone/calcipotriol (BFH 772) / Novartis
A case of IgA pemphigus in a patient with a history of psoriasis (e-Poster Hall) - Aug 8, 2023 - Abstract #EADV2023EADV_1554;
A year ago, he was diagnosed with psoriasis at another hospital and was undergoing oral cyclosporine, topical betamethasone/calcipotriol and tacrolimus treatment. Dermatologists managing patients with psoriasis should be aware of this epidemiological feature that bullous diseases can be associated with psoriasis, and prospective studies are required to further delineate their relation.
- | betamethasone/calcipotriol (BFH 772) / Novartis
Journal: Fractional CO2 Laser versus Fractional CO2 Laser Plus Betamethasone/Calcipotriol Ointment in the Treatment of Nail Psoriasis. (Pubmed Central) - May 7, 2023
Dermatologists managing patients with psoriasis should be aware of this epidemiological feature that bullous diseases can be associated with psoriasis, and prospective studies are required to further delineate their relation. Fractional CO2 laser can be an effective and promising new treatment for nail psoriasis.
- Duobrii (halobetasol/tazarotene) / Bausch Health
Cost-Effectiveness Analysis of Halobetasol and Tazarotene (DUOBRIITM) Compared to Standard of Care for Adult Patients with Moderate-to-Severe Plaque Psoriasis in Qu () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_1690;
The SoC (betamethasone/calcipotriol [BD/VDA] followed by [>] systemic therapy [ST]; [BD/VDA>ST]) was compared to HP/TAZ>ST. Considering the chronic nature of plaque psoriasis, adding HP/TAZ to SoC would lead to considerable long-term savings in Quebec while improving population health.
- || betamethasone/calcipotriol (BFH 772) / Novartis, Enstilar (calcipotriene/betamethasone dipropionate) / LEO Pharma
Clinical, Observational data, Journal: Prospective Observational Evaluation of Fixed Combination Calcipotriol/Betamethasone Aerosol Foam (Enstilar (Pubmed Central) - Mar 6, 2023
Considering the chronic nature of plaque psoriasis, adding HP/TAZ to SoC would lead to considerable long-term savings in Quebec while improving population health. This study demonstrated the effectiveness, rapid onset of action, good tolerability, and good safety profile of the Cal/BD aerosol foam in patients with scalp psoriasis treated in a real-world setting.
- | betamethasone/calcipotriol (BFH 772) / Novartis
Journal: Efficacy of Calcipotriol/Betamethasone Dipropionate Fixed-Combination Aerosol Foam in the Treatment of Localized Scalp Psoriasis: A Real-Life Case Series from Switzerland. (Pubmed Central) - Aug 25, 2022
Our case series confirms that Cal/BD foam is a rapid, effective, and convenient treatment for localized scalp psoriasis in a nonselected real-world patient cohort refractory to TCS or other local treatments. Clear application instructions are crucial for treatment success and cosmetic acceptance, however.
- | Enstilar (calcipotriene/betamethasone dipropionate) / LEO Pharma
Journal: Sub-population analysis of patients with plaque psoriasis treated with calcipotriol/betamethasone aerosol foam; effectiveness and patient satisfaction, according to baseline disease severity and prior psoriasis treatment experience, in a Greek population. (Pubmed Central) - Jun 9, 2022
The greatest reductions were observed in treatment-naïve patients with severe disease. Clinically relevant benefits were observed with Cal/BD aerosol foam in psoriasis patients, regardless of prior treatment-experience and disease severity at baseline.
- | betamethasone/calcipotriol (BFH 772) / Novartis
Journal: Pulse-Dye Laser Followed by Betamethasone-Calcipotriol and Fractional Ablative CO2-Laser-Assisted Delivery for Nail Psoriasis. (Pubmed Central) - Aug 18, 2021
Clinically relevant benefits were observed with Cal/BD aerosol foam in psoriasis patients, regardless of prior treatment-experience and disease severity at baseline. Combined PDL and fractional ablative CO2-LADD of betamethasone-calcipotriol gel should be considered for the treatment of nail psoriasis.
- | calcipotriol/betamethasone dipropionate / Generic mfg.
Preclinical, Journal: Sensitivity of Different In Vitro Performance Tests and Their In Vivo Relevance for Calcipotriol/Betamethasone Ointment. (Pubmed Central) - Dec 20, 2020
The results of in vitro experiments rank orderly correlated with the results of clinical study. In vitro methods are more sensitive and highly discriminatory when compared to in vivo performance.
- || calcipotriol/betamethasone dipropionate / Generic mfg.
Clinical, Journal: Efficacy of Calcipotriol-Betamethasone Ointment in Patients with Mild to Moderate Plaque Psoriasis: Subgroup Analyses. (Pubmed Central) - Apr 16, 2020
Increased BMI and obesity present risk factors for reduced treatment effectiveness. Importantly, the efficacy of calcipotriol-betamethasone ointment was consistent in all subgroups.
- || calcipotriol/betamethasone dipropionate / Generic mfg.
Clinical, Journal: Patient and Physician Satisfaction with Calcipotriol and Betamethasone Dipropionate Aerosol Foam in the Treatment of Plaque Psoriasis on the Body. (Pubmed Central) - Apr 12, 2020
Importantly, the efficacy of calcipotriol-betamethasone ointment was consistent in all subgroups. Both patients and physicians expressed high satisfaction with the use of Cal/BD aerosol foam for the treatment of plaque psoriasis on the body.
- | betamethasone/calcipotriol (BFH 772) / Novartis, Humira (adalimumab) / Eisai, AbbVie
Preclinical, Journal: Differential effects of phototherapy, adalimumab and betamethasone/calcipotriol on effector and regulatory T cells in psoriasis. (Pubmed Central) - Oct 24, 2019
Both patients and physicians expressed high satisfaction with the use of Cal/BD aerosol foam for the treatment of plaque psoriasis on the body. The differential effects reported here for the above-mentioned treatment modalities could be exploited to optimize or design therapeutic strategies to better overcome the inflammatory drivers and restore the Th17/Treg balance in psoriasis.
- | betamethasone/calcipotriol (BFH 772) / Novartis
Trial completion: Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients (clinicaltrials.gov) - Apr 26, 2012
P2, N=36, Completed, Sponsor: Novartis Pharmaceuticals
The differential effects reported here for the above-mentioned treatment modalities could be exploited to optimize or design therapeutic strategies to better overcome the inflammatory drivers and restore the Th17/Treg balance in psoriasis. Recruiting --> Completed
- | betamethasone/calcipotriol (BFH 772) / Novartis
New P2 trial: Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients (clinicaltrials.gov) - Sep 18, 2011
P2, N=36, Completed, Sponsor: Novartis Pharmaceuticals